The DOI matches its Crossref record.
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
Abstract
The pharmacokinetics of a novel antipsychotic agent, risperidone, and the prolactin response were studied in 12 dextromethorphan-phenotyped healthy men after administration of 1 mg risperidone intravenously, intramuscularly, and orally. The formation of the equipotent major metabolite, 9-hydroxyrisperidone, exhibited CYP2D6-related polymorphism. The plasma area under the concentration-time curve from time zero to infinity ratio of 9-hydroxyrisperidone to risperidone averaged 3 (intravenous and intramuscular) and 6 (oral administration) in the extensive metabolizers and 0.2 in the poor metabolizers. Risperidone half-life was about 3 hours in extensive metabolizers and 22 hours in poor metabolizers. Risperidone absolute oral bioavailability was 66%. The pharmacokinetics of the active moiety (risperidone plus 9-hydroxyrisperidone) varied little among subjects (mean terminal half-life, 20 +/- 2 1/2 hours; absolute oral and intramuscular bioavailability, 100%). The prolactin response correlated best with the plasma active moiety, which showed little hysteresis. It is concluded that risperidone metabolic polymorphism on increased plasma prolactin is minimal and that the active moiety is clinically relevant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Summary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Kapur, S., Zipursky, R. B., & Remington, G. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 712
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00127-0 · Cited by 350
de Leon, J., Susce, M. T., Pan, R.-M., Fairchild, M., Koch, W. H., & Wedlund, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0103 · Cited by 319
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review
Spina, E., & De Leon, J. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00017.x · Cited by 271
Wachtel, S. R., Ortengren, A., & Wit, H. D. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00104-7 · Cited by 138
Konarzewska, B., Wołczyński, S., Szulc, A., Galińska, B., Popławska, R., & Waszkiewicz, N. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.015 · Cited by 70
“The novel antipsychotic drug risperidone elevates PRL (Huang et al., 1993; Breier et al., 1999; Dickson and Glazer, 1999; Meaney and O’Keane, 2002; Brunellsechi et al., 2003) and may actually produce more severe hyperprolactinemia than conventional agents.”
BackgroundLaffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.366 · Cited by 26
Metadata
- Authors
- Huang, M.-L., Peer, A. V., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A. I., Zylicz, Z., Visscher, H. W., & Jonkman, J. H. G.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1993
- Volume
- 54
- Issue
- 3
- Pages
- 257-268
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1964688493
- Cited by
- 316
- References
- 0
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.